World's Best Scientists 2026 revealed!
Award Badge
Immunology
UK
2026
Award Badge
Medicine
UK
2026

D-Index & Metrics

Immunology

D-Index
155
Citations
100618
World Ranking
103
National Ranking
10

Medicine

D-Index
155
Citations
100768
World Ranking
951
National Ranking
99

Marc Feldmann publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Marc Feldmann sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 789 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Marc Feldmann D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Marc Feldmann sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 155 D-Index — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in United Kingdom Leader Award
  • 2026 - Research.com Medicine in United Kingdom Leader Award
  • 2025 - Research.com Immunology in United Kingdom Leader Award
  • 2025 - Research.com Medicine in United Kingdom Leader Award
  • 2023 - Research.com Medicine in United Kingdom Leader Award
  • 2022 - Research.com Immunology in United Kingdom Leader Award
  • 2020 - Distinguished Fellows of the American Association of Immunologists (AAI)
  • 2014 - Canada Gairdner International Award
  • 2010 - Member of the National Academy of Sciences
  • 2008 - Dr. Paul Janssen Award for Biomedical Research, Johnson & Johnson for their role in the discovery of tumor necrosis factor-alpha, or TNF-alpha, as an effective therapeutic target for rheumatoid arthritis and other autoimmune diseases.
  • 2006 - Fellow of the Royal Society, United Kingdom
  • Member of the Association of American Physicians
  • Member of the European Molecular Biology Organization (EMBO)
  • Member of the Association of American Physicians
  • Member of the European Molecular Biology Organization (EMBO)
  • Member of the Association of American Physicians
  • Member of the European Molecular Biology Organization (EMBO)
  • Member of the Association of American Physicians
  • Member of the European Molecular Biology Organization (EMBO)

Overview

Marc Feldmann is affiliated with the University of Oxford in the United Kingdom and primarily works in the field of Medicine. Their research spans several subfields including Infectious Diseases, Neurology, Immunology, Rheumatology, and Surgery.

The scientist has contributed to topics related to COVID-19 Clinical Research Studies, Long-Term Effects of COVID-19, SARS-CoV-2 and COVID-19 Research, Dupuytren's Contracture and Treatments, Inflammasome and immune disorders, as well as Cannabis and Cannabinoid Research. Their work addresses significant medical challenges with focused studies in inflammation and immune responses.

Significant recent publications by Marc Feldmann include:

  • "An inflammatory cytokine signature predicts COVID-19 severity and survival", 2020, Nature Medicine
  • "Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed", 2020, The Lancet
  • "Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19", 2020, Science Immunology
  • "COVID-19 therapeutics: Challenges and directions for the future", 2022, Proceedings of the National Academy of Sciences
  • "Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment", 2020, The Lancet Rheumatology

Frequent co-authors who have collaborated with Feldmann include Jagdeep Nanchahal, Lynn Williams, T. B. Layton, Fiona E. McCann, and Tracy Hussell.

Major venues where their research has been published encompass:

  • Proceedings of the National Academy of Sciences
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nature Communications
  • The Lancet Rheumatology
  • NIHR Open Research

Over the course of their career, Feldmann has received multiple recognitions and awards such as Distinguished Fellow of the American Association of Immunologists (AAI) in 2020, the Canada Gairdner International Award in 2014, membership in the National Academy of Sciences since 2010, the Dr. Paul Janssen Award for Biomedical Research from Johnson & Johnson in 2008 for work identifying tumor necrosis factor-alpha as a therapeutic target in autoimmune diseases, Fellowship of the Royal Society in the United Kingdom since 2006, membership in the Association of American Physicians, and membership in the European Molecular Biology Organization (EMBO).

Best Publications

  • Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

    P E Lipsky;D M van der Heijde;E W St Clair;D E Furst

  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

    R Maini;E W St Clair;F Breedveld;D Furst

  • ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS

    Marc Feldmann;Fionula M. Brennan;Ravinder N. Maini

  • An inflammatory cytokine signature predicts COVID-19 severity and survival.

    Diane Marie Del Valle;Seunghee Kim-Schulze;Hsin-Hui Huang;Noam D. Beckmann

  • Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.

    M J Elliott;R N Maini;M Feldmann;J R Kalden

  • Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.

    Ravinder N. Maini;Ferdinand C. Breedveld;Joachim R. Kalden;Josef S. Smolen

  • Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

    Marc Feldmann;Ravinder N. Maini

  • IRF5 Promotes Inflammatory Macrophage Polarization and TH1-TH17 Responses

    Thomas Krausgruber;Katrina Blazek;Timothy Smallie;Saba Alzabin

  • ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY

    G F Bottazzo;R Pujol-Borrell;T Hanafusa;M Feldmann

  • Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha

    M J Elliott;R N Maini;M Feldmann;A Long-Fox

  • Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

    Richard O. Williams;Marc Feldmann;Ravinder N. Maini

  • Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

    F M Brennan;D Chantry;A Jackson;R Maini

  • Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis

    T Hirano;T Matsuda;M Turner;N Miyasaka

  • Rheumatoid Arthritis

    Unknown

  • Role of interleukin-1beta in postoperative cognitive dysfunction.

    Mario Cibelli;Antonio Rei Fidalgo;Niccolò Terrando;Niccolò Terrando;Daqing Ma

  • Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis

    M J Elliott;R N Maini;M Feldmann;A Long-Fox

  • Development of anti-TNF therapy for rheumatoid arthritis

    Marc Feldmann

  • The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

    A. M. Malfait;R. Gallily;P. F. Sumariwalla;A. S. Malik

  • Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases.

    Marc Feldmann;Ravinder N Maini

  • Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline.

    Niccolò Terrando;Claudia Monaco;Daqing Ma;Brian M. J. Foxwell

  • Assessment of antibodies to double‐stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open‐label and randomized placebo‐controlled trials

    P. J. Charles;R. J. T. Smeenk;J. De Jong;M. Feldmann

  • IRF5 PROMOTES INFLAMMATORY MACROPHAGE POLARIZATION AND TH1/TH17 RESPONSE

    T Krausgruber;K Blazek;T Smallie;H Lockstone

Frequent Co-Authors

Fionula M. Brennan
Fionula M. Brennan University of Oxford
Ravinder N. Maini
Ravinder N. Maini Imperial College London
Brian M. J. Foxwell
Brian M. J. Foxwell Imperial College London
Richard O. Williams
Richard O. Williams University of Oxford
Ewa M. Paleolog
Ewa M. Paleolog University of Oxford
Marco Londei
Marco Londei University College London
Peter Erb
Peter Erb University of Basel
Martin R. Turner
Martin R. Turner University of Oxford
Peter C. Taylor
Peter C. Taylor University of Oxford
Evangelos Andreakos
Evangelos Andreakos Academy of Athens

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, exploring related online degrees can open diverse career opportunities in healthcare and research. Nurse practitioner programs, especially online, offer flexible pathways to advance clinical expertise. If you're considering a nursing path, programs highlighted as easy nurse practitioner programs to get into can help kickstart your clinical career with practical, accessible options.

For specialization in mental health, psychiatric nurse practitioner degrees are a strong complement to Immunology knowledge. Top-ranked options with excellent clinical site support can be found among the top pmhnp programs, ensuring hands-on experience vital for patient care. For students mindful of budget, there are also cheapest pmhnp programs that balance cost-effectiveness with quality education.

Understanding the financial outlook is crucial when choosing a path. The dnp salary by state information provides valuable insights into the earning potential across different regions. This data helps guide decisions on where to study and work post-graduation, aligning your Immunology background with rewarding career possibilities.

Best Scientists Citing Marc Feldmann

Trending Scientists